Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835470 | 0.76 | — | — | |
| SCHEMBL10710705 | 0.70 | — | — | |
| SCHEMBL10504306 | 0.65 | — | — | |
| SCHEMBL29001365 | 0.65 | TSHR (0.34) | FFAR3 | |
| SCHEMBL25055640 | 0.61 | CYP1A2 (0.39) | — | |
| SCHEMBL19743253 | 0.61 | KMT2A (0.47) | — | |
| SCHEMBL25055580 | 0.61 | CYP3A4 (0.35) | — | |
| SCHEMBL28616020 | 0.61 | — | — | |
| SCHEMBL2055540 | 0.61 | FFAR3 (0.62) | FFAR3 | |
| SCHEMBL25055728 | 0.60 | CYP1A2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2025-08-21 | — | — | US | disclosed |
| EP-4293112-A2 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | Genzyme Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3597655-B1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORP (US) | 2023-08-02 | — | — | EP | disclosed |
| US-10907142-B2 | Oligosaccharides comprising an aminooxy group and conjugates thereof | GENZYME CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| EP-2457919-B1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORP (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2416799-B1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | TUFTS MEDICAL CT INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2457920-B1 | Oligosaccharides comprising an aminooxy group and conjugates thereof | GENZYME CORP (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170065668-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | TUFTS MEDICAL CENTER, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170014520-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2017-01-19 | — | — | US | disclosed |
| WO-2006083317-A9 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060122267-A1 | Compositions and methods for attenuating mitochondria-mediated cell injury | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-08 | — | — | US | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10907142-B2 | Oligosaccharides comprising an aminooxy group and conjugates thereof | MAN2B1, MAN1B1, GAA | FFAR3 1437/4885 |
| US-20170065668-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | F2R, F2RL1, PLAT | FFAR3 1875/4885 |
| US-20170014520-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | FFAR3 1437/4885 |
| US-20060122267-A1 | Compositions and methods for attenuating mitochondria-mediated cell injury | SHMT2, TXN2, TXNRD2 | FFAR3 1474/4885 |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | FFAR3 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.